INOTREM
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced today that it has obtained authorization to launch its phase IIa clinical trial in COVID-19 patients in France, Belgium and the USA.
For this study, Inotrem received a non-dilutive funding as part of the call for proposals PSPC Covid, financed by the Investments d’Avenir Program which managed on behalf of the French government by Bpifrance, France’s public investment bank. Inotrem with its partners the CHRU of Nancy and the CHU of Limoges, was one of the 6 French biotech companies who benefited from this programme to support the research and development of therapeutic solutions targeting COVID-19.
The goal of this first exploratory study is to determine the safety and tolerability and potential signals of efficacy of nangibotide in critically ill patients with COVID-19 with features of systemic inflammation. The objective of this project is to have a positive impact on the severity of the respiratory failure, reduce duration of mechanical ventilation, length of stay in ICU and reduce mortality. Sixty patients will be enrolled in Europe and in the United States. This study follows an observational study in 27 patients, conducted by Prof. Sébastien Gibot at the CHRU of Nancy, which showed an increased expression of the TREM-1 pathway in severe COVID-19 patients. TREM-1 is an immunomodulatory receptor expressed on innate immune cells which amplifies and maintains inflammation.
Previous clinical studies with nangibotide demonstrated its safety and tolerability in patients suffering from septic shock, which is also characterized by a systemic inflammatory reaction. Pre-clinical models have shown that nangibotide inhibits the amplification of the immune response caused by the activation of TREM-1 and was able to restore appropriate inflammatory response, vascular function, and improved survival in septic shock models. Inotrem is currently conducting a Phase IIb trial (ASTONISH) to treat septic shock patients with nangibotide in 6 European countries and in the United States. It is also developing, with Roche Diagnostics, a companion diagnostic test to identify septic schock patients more likely to benefit from its nangibotide treatment.
Coronavirus disease 2019 is a new pandemic disease that arises as a consequence of infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The optimum treatment strategy in the management of critically ill patients with COVID-19 continues to evolve and, in addition to supportive therapies such as mechanical ventilation, vasopressors and renal replacement therapy, may include immunomodulatory approaches, such as nangibotide, in patients with severe disease.
Professor Sébastien Gibot, Nancy University Hospital and coordinating investigator said “We observed that the TREM-1 pathway was activated in severe forms of COVID-19. Nangibotide is a TREM-1 inhibitor and has the potential to restore an appropriate immune response. We are hoping to demonstrate that nangibotide will reduce the duration of hospitalization and mortality of critically ill patients suffering from COVID-19”.
Jean-Jacques Garaud, CEO of Inotrem, declared: “We are very pleased with both the granting of this financial support and the clearance to start our clinical trial. The French administration has been very effective in working in a coordinated and rapid fashion.”
About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
www.inotrem.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005598/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LRN Sponsors 2025 Nordic Ethics & Compliance Survey to Advance Region-Specific Insights on Responsible Business Conduct24.11.2025 10:00:00 CET | Press release
LRN and Nordic Business Ethics partner to elevate region-specific insights that strengthen global E&C effectiveness LRN Corporation, a leader in ethics and compliance (E&C) solutions, announced its sponsorship of the 2025 Nordic Ethics & Compliance Survey, an annual study by Nordic Business Ethics examining how organizations across the Nordic region integrate ethics, responsibility, and compliance into daily decision-making. LRN’s sponsorship supports the survey’s mission to highlight regional insights that enrich global understanding of workplace ethics. The partnership reflects LRN’s belief that effective E&C programs are not a one-size-fits-all solution and must be informed by regional cultural norms and organizational identity. The survey data shows that while Nordic organizations excel in values-driven ethics, their experience mirrors a global trend of increased regulatory expectations and company growth straining operational systems and governance structures. “Nordic organization
IonQ Appoints Dr. Marco Pistoia as CEO of IonQ Italia to Spearhead Strategic Quantum Initiatives Across the Country24.11.2025 09:00:00 CET | Press release
Industry veteran Pistoia to drive enterprise and research engagement as IonQ deepens investment in Italy’s quantum future IonQ (NYSE: IONQ), the world’s leading quantum company, today announced the appointment of Dr. Marco Pistoia, Ph.D., as Chief Executive Officer of IonQ Italia S.r.l., a wholly owned subsidiary. Dr. Pistoia will lead IonQ’s strategic initiatives in Italy, building on the company’s momentum as the world’s only full-stack quantum platform provider across quantum computing, quantum networking, quantum sensing, and quantum security. IonQ Italia will help establish Italy as a dynamic powerhouse in the global quantum landscape. Dr. Pistoia and his team will focus on expanding access to IonQ’s advanced quantum systems for Italian enterprises, research institutions, and government partners. The team will be tasked with driving innovation in quantum applications for key sectors such as finance, energy, aerospace, defense, pharmaceuticals, and advanced manufacturing. “Italy is
Global Youth Invited To Apply for Doha Debates Ambassador Program24.11.2025 07:45:00 CET | Press release
Unique virtual program empowers young changemakers with communication, collaboration, and problem-solving skills Qatar Foundation’s Doha Debates is inviting global youth ages 18–26 to apply for the eighth cohort of its international ambassador program. This 12-week virtual experience empowers participants to engage in constructive dialogue, collaborate on solutions to global challenges and form lasting relationships with other emerging leaders. The application deadline is December 15, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251123068415/en/ Global youth are invited to apply for the Doha Debates Ambassador Program, a unique virtual experience that equips young changemakers with communication, collaboration, and problem-solving skills. (Photo: AETOSWire) The upcoming cohort begins with a four-week Community of Practice from January 20 to February 10, 2026, followed by the official Ambassador Program from February
Brown Brothers Media Acquires European Startup Media Platform Silicon Canals24.11.2025 03:23:00 CET | Press release
Brown Brothers Media, a Singapore-based digital publisher, announces the acquisition of SiliconCanals.com, the European technology startup media platform and community founded by Remco Janssen and operated under Proudly Media. The six-figure, asset-based deal marks a new chapter for the 11-year-old Dutch media brand, which has grown into one of Europe’s leading voices in the startup and innovation ecosystem. Founded in 2014, Silicon Canals has established itself as a go-to source for news and insights on Europe’s tech, venture capital, and startup scene. The acquisition follows recent shifts in the European tech media landscape, including the closure of The Next Web’s editorial operations and MeOut Group’s earlier acquisition of EU-Startups. “After more than a decade building Silicon Canals into a trusted platform connecting Europe’s founders, innovators, and investors, it was time to pass the baton to a full-fledged, long-term media house,” said Remco Janssen, founder and CEO of Proud
IFF Introduces Smart Dosing Robot to Transform Fragrance Production24.11.2025 02:00:00 CET | Press release
New technology delivers quicker, more precise creative sampling for IFF customers across Greater Asia. IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences, has implemented the Colibri robot in its Chin Bee production facility. This advanced industrial dosing system can produce fragrance sample batches on demand in minutes, reimagining and expediting the fragrance development journey for local, regional and global customers in Greater Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251123090457/en/ Photo credit: IFF - Colleagues at IFF Chin Bee with the site's new smart-dosing robot. The new robotic system, installed at the company's cross-category Scent and Taste production plant in Chin Bee, Singapore, accelerates the path from ideation to formulation for fragrance creation. Replacing the previous system, it handles multiple ingredients simultaneously, operates four times
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom